Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Exicure, Inc. XCUR

Healthcare  —  Biotechnology
1.22 (0.01) (0.81%) as of 25 Sep
Market cap
$8.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Exicure, Inc. (XCUR) Business Profile

Updated before January 2025

Company Overview

Exicure, Inc. (XCUR) is a biotechnology company that specializes in developing innovative therapeutics based on its proprietary spherical nucleic acid (SNA) technology. Founded in 2011, the company is headquartered in Chicago, Illinois, and has established itself as a pioneer in the field of nucleic acid therapeutics. Exicure’s mission is to address unmet medical needs by leveraging its unique platform to develop treatments for genetic disorders, oncology, and other therapeutic areas. The company was co-founded by Chad A. Mirkin, a renowned chemist and nanotechnology expert, whose groundbreaking research laid the foundation for Exicure’s SNA technology. Key leadership includes CEO Matthias Schroff, who brings extensive experience in the biotechnology sector, and a team of seasoned executives and scientists dedicated to advancing the company’s innovative pipeline.

Core Business Segments

Exicure operates primarily in the biotechnology and pharmaceutical sectors, focusing on the development of therapeutics based on its SNA platform. The company’s core business segments include:

1. Genetic Disorders

Exicure is actively developing therapies for genetic disorders by targeting the root causes of these conditions. Its lead candidate in this segment is XCUR-FXN, a treatment for Friedreich’s ataxia, a rare genetic disease that affects the nervous system and movement. The company aims to address other genetic disorders in the future using its SNA technology.

2. Oncology

Exicure is exploring the application of its SNA platform in oncology to develop treatments that can effectively target cancer cells while minimizing side effects. The company has previously worked on candidates such as AST-008, an immuno-oncology therapeutic designed to activate the immune system against tumors.

3. Neurological Disorders

The company is also investigating the potential of its SNA technology in treating neurological disorders. By delivering nucleic acids to specific regions of the brain, Exicure aims to address diseases that have been challenging to treat with conventional therapies.

4. Partnerships and Collaborations

Exicure collaborates with other pharmaceutical and biotechnology companies to expand the applications of its SNA technology. These partnerships enable the company to explore new therapeutic areas and leverage external expertise and resources.

Business Model

Exicure’s business model revolves around the development and commercialization of therapeutics based on its proprietary SNA platform. The company generates revenue through:

  • Research and Development (R&D) Collaborations: Exicure partners with other companies to co-develop therapies, sharing the costs and benefits of these initiatives.
  • Licensing Agreements: The company licenses its SNA technology to other organizations, earning royalties and milestone payments.
  • Product Sales: Once its therapeutic candidates receive regulatory approval, Exicure plans to generate revenue through the sale of these products.

Exicure’s approach integrates cutting-edge science with strategic partnerships to maximize the potential of its technology and bring innovative treatments to market.

Strategic Direction

Exicure is focused on advancing its pipeline of therapeutic candidates and expanding the applications of its SNA platform. Key strategic priorities include:

  • Pipeline Expansion: The company aims to develop additional candidates for genetic disorders, oncology, and neurological diseases.
  • Partnership Growth: Exicure plans to establish new collaborations with pharmaceutical and biotechnology companies to accelerate the development of its therapies.
  • Sustainability Goals: The company is committed to conducting its operations in an environmentally and socially responsible manner, aligning with industry best practices.
  • Global Reach: Exicure seeks to expand its presence in international markets, ensuring that its therapies are accessible to patients worldwide.

Competitive Landscape

Exicure operates in a highly competitive biotechnology sector, facing competition from companies that develop nucleic acid-based therapeutics and other innovative treatments. Key competitors include:

  • Ionis Pharmaceuticals: A leader in RNA-targeted therapeutics with a robust pipeline of antisense oligonucleotide drugs.
  • Alnylam Pharmaceuticals: Specializes in RNA interference (RNAi) therapeutics for genetic and rare diseases.
  • Moderna: Known for its mRNA technology, which has applications in vaccines and therapeutics.
  • BioNTech: Focuses on mRNA-based therapies and immuno-oncology treatments.

Exicure differentiates itself through its proprietary SNA technology, which offers unique advantages in terms of stability, delivery, and efficacy.

Risk Factors

Exicure faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Challenges: The development and approval of new therapeutics are subject to stringent regulatory requirements, which can delay or prevent product launches.
  • Market Dependence: The company’s success depends on the commercial viability of its therapeutic candidates, which are still in the development stage.
  • Supply Chain Disruptions: Exicure relies on third-party suppliers and manufacturers, making it vulnerable to disruptions in the supply chain.
  • Competition: The biotechnology sector is highly competitive, with many companies vying for market share in similar therapeutic areas.
  • Financial Risks: As a pre-commercial company, Exicure depends on external funding to finance its operations, which may not always be readily available.

Recent Developments

Exicure has made significant progress in advancing its pipeline and refining its strategic focus. Recent developments include:

  • Pipeline Updates: The company has prioritized the development of XCUR-FXN for Friedreich’s ataxia, reflecting its commitment to addressing unmet medical needs.
  • Corporate Restructuring: Exicure has streamlined its operations to focus on its core therapeutic areas, improving efficiency and resource allocation.
  • Partnerships: The company has entered into new collaborations to explore additional applications of its SNA technology.
  • Global Events: The COVID-19 pandemic has highlighted the importance of innovative therapeutics, reinforcing Exicure’s mission to develop groundbreaking treatments.

Investment Considerations

Investors considering Exicure should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Exicure’s SNA platform offers unique advantages in drug development.
  • Strong Pipeline: The company has a promising pipeline of therapeutic candidates targeting high-value markets.
  • Experienced Leadership: Exicure’s management team has a proven track record in the biotechnology sector.
  • Collaborative Approach: Partnerships with other companies enhance the company’s capabilities and market reach.

Risks

  • Early-Stage Company: Exicure’s therapeutic candidates are still in development, with no products currently on the market.
  • Financial Dependence: The company relies on external funding to sustain its operations.
  • Regulatory and Market Risks: The success of Exicure’s therapies depends on regulatory approval and market acceptance.

Conclusion

Exicure, Inc. is a pioneering biotechnology company with a unique platform technology and a strong commitment to addressing unmet medical needs. While the company faces challenges typical of early-stage biotech firms, its innovative approach, experienced leadership, and strategic partnerships position it for long-term success. As Exicure continues to advance its pipeline and expand its market presence, it remains a compelling player in the biotechnology sector with significant growth potential.